Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6464822 | 0.92 | ERN1 (0.42) | ERN1ALDH1A1MAPTEGFRBACE1 | |
| SCHEMBL6683960 | 0.88 | ERN1 (0.46) | ERN1ALDH1A1MAPTEGFRBACE1 | |
| SCHEMBL6462608 | 0.84 | ERN1 (0.38) | ERN1ALDH1A1MAPTEGFR | |
| SCHEMBL8686048 | 0.71 | ALDH1A1 (0.55) | ERN1ALDH1A1MAPTBACE1 | |
| SCHEMBL31254214 | 0.71 | ALDH1A1 (0.55) | ERN1ALDH1A1MAPTBACE1 | |
| SCHEMBL6459781 | 0.71 | ERN1 (0.44) | ERN1ALDH1A1MAPT | |
| SCHEMBL6684140 | 0.68 | PTGDR2 (0.38) | ERN1 | |
| SCHEMBL16815269 | 0.66 | ALDH1A1 (0.43) | ERN1ALDH1A1MAPTBACE1 | |
| SCHEMBL16097864 | 0.65 | ERN1 (0.44) | ERN1ALDH1A1MAPTBACE1 | |
| SCHEMBL23393432 | 0.64 | PTGDR2 (0.47) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203094-A1 | 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | AXYS PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | disclosed |
| EP-1474400-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)] -6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003068756-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)]-6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203094-A1 | 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | F7, HABP2, F13B | ERN1 3512/4885ALDH1A1 1830/4885MAPT 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.